DQ2 --- Response to Rehana

Thank you Rehana, for that was a well put discussion and I especially like the last part about training being essential and I would like to respond to that.

In as much as I agree that training is important to leadership and indeed the reason why we are studying these practices, but that may all be for naught if the culture and apparatus of the organization or body does not support the ethical practices of a leader. One mechanism that I find getting maligned is the policy of whistle blowers. In the developed world, mostly the United States, a lot of people come out to whistle blow on big pharma companies that have unethical practices especially in clinical trial that endanger lives. For instance, Johnson & Johnson illegally and effectively promoted the use of Propulsid for children despite internal documentation that showed its safety concern (Brezis, 2008). The government policy at the time protected these individuals and promoted the practice and over time created more open policy in how the pharmaceutical world of drug development works, however these policies are not always implemented as the whistle blowers are seen as disloyal and treasonous in some cases (Martin, 2003). Therefore, in order to ethical leaders, one needs to examine the mechanism of accountability in regard to whistle blowers.

References

Brezis, M. (2008). Big pharma and health care: unsolvable conflict of interests between private enterprise and public health. *Israeli Journal of Psychiatry Relat Sci*, *45*(2), 83–94. Retrieved from https://pdfs.semanticscholar.org/9b78/b9f4cd42347e827fdf800fe5b9122150d6c0.pdf

Martin, B. (2003). Illusions of Whistleblower Protection. *UTS Law Review*, *5*. Retrieved from https://heinonline.org/HOL/Page?handle=hein.journals/utslr5&id=119&div=&collection=